PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan.\', \'iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.\', \'Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.\', \'Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan.\', \'National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Japan.\', \'R&D Center, ID Pharma Co., Ltd., Tsukuba, Japan.\', \'Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/2211-5463.13153
?:doi
?:hasPublicationType
?:journal
  • FEBS open bio
is ?:pmid of
?:pmid
?:pmid
  • 33822489
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.884
?:rankingScore_hIndex
  • 21
is ?:relation_isRelatedTo_publication of
?:title
  • iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33822489>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33822489>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all